Brandywine Global Investment Management, LLC Biogen Inc. Transaction History

Brandywine Global Investment Management, LLC

$13 Billion
Q2 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$222.59 - $267.94 $758,586 - $913,139	-3,408 Reduced 4.64%	70,041 $18.1 Million
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $1.59 Million - $1.8 Million	6,284 Added 9.36%	73,449 $18.9 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $420,582 - $485,995	1,528 Added 2.33%	67,165 $19.1 Million
Q1 2023 May 12, 2023	SELL	$256.56 - $292.34 $633,446 - $721,787	-2,469 Reduced 3.63%	65,637 $18.2 Million
Q4 2022 Feb 10, 2023	SELL	$252.44 - $306.72 $1.23 Million - $1.49 Million	-4,854 Reduced 6.65%	68,106 $18.9 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $4.64 Million - $6.4 Million	23,831 Added 48.51%	72,960 $19.5 Million
Q2 2022 Aug 11, 2022	SELL	$187.54 - $223.02 $103,897 - $123,553	-554 Reduced 1.12%	49,129 $10 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $19.5 Million - $24.6 Million	-100,637 Reduced 66.95%	49,683 $10.5 Million
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $601,896 - $773,525	-2,688 Reduced 1.76%	150,320 $36.1 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $29.2 Million - $38.1 Million	103,159 Added 206.94%	153,008 $43.3 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $2.4 Million - $3.84 Million	9,268 Added 22.84%	49,849 $17.3 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $16.8 Million - $19.7 Million	-69,136 Reduced 63.01%	40,581 $11.4 Million
Q4 2020 Feb 10, 2021	SELL	$236.26 - $355.63 $30.9 Million - $46.4 Million	-130,608 Reduced 54.35%	109,717 $26.9 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $15.2 Million - $17.6 Million	57,409 Added 31.39%	240,325 $68.2 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $4.04 Million - $5.35 Million	15,632 Added 9.34%	182,916 $48.9 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $42.5 Million - $53.9 Million	158,083 Added 1718.11%	167,284 $52.9 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $2.01 Million - $2.77 Million	9,112 Added 10238.2%	9,201 $2.71 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $8 Million - $8.97 Million	-36,781 Reduced 99.76%	89 $21,000
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $38.8 Million - $42.8 Million	-176,890 Reduced 82.75%	36,870 $8.62 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $4.76 Million - $7.44 Million	21,942 Added 11.44%	213,760 $50.5 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $546,417 - $692,095	-1,962 Reduced 1.01%	191,818 $57.7 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $1.77 Million - $2.32 Million	-6,041 Reduced 3.02%	193,780 $68.5 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $1.02 Million - $1.21 Million	-3,954 Reduced 1.94%	199,821 $58 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $3.4 Million - $4.81 Million	13,083 Added 6.86%	203,775 $55.8 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $1.81 Million - $2.03 Million	5,899 Added 3.19%	190,692 $60.7 Million
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $1.95 Million - $2.28 Million	-6,930 Reduced 3.61%	184,793 $57.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	191,723	191,723 $52 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandywine Global Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brandywine Global Investment Management, LLC with notifications on news.

Account